South Korea Anti-Peptic Ulcer Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Proton Pump Inhibitors, H2-Receptor Antagonists, Antacids, Antibiotics, and Others), By Ulcer Type (Gastric Ulcer, Duodenal Ulcer, Esophageal Ulcer, and Others), and South Korea Anti-Peptic Ulcer Drugs Market Insights, Industry Trend, Forecasts to 2035

South Korea Anti-Peptic Ulcer Drugs Market Insights Forecasts to 2035

• The South Korea Anti-Peptic Ulcer Drugs Market Size is Expected to Grow at a CAGR of around 4.6% from 2025 to 2035
• The South Korea Anti-Peptic Ulcer Drugs Market Size is Expected to hold a significant Share by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Anti-Peptic Ulcer Drugs Market Size is Anticipated to Grow at a CAGR of 4.6% from 2025 to 2035. The market is driven by rising prevalence of gastric and duodenal ulcers along with increasing adoption of proton pump inhibitors and H2 receptor antagonists. Growing healthcare expenditure, lifestyle changes, and supportive government initiatives further fuel market growth.

Market Overview

The South Korea anti-peptic ulcer drugs market relates to the pharmaceutical class that develops, distributes, and utilizes drugs that relevant to the treatment of peptic ulcers, both gastric and duodenal ulcers, by suppressing the secretion of gastric acid and inducing mucosal healing.  The anti-peptic ulcer drugs market in South Korea has been growing due to increasing incidences of gastrointestinal disorders as a result of dietary changes, stress levels, and increased incidents of Helicobacter pylori infection. In addition, a price decrease in the utilization of proton pump inhibitors (PPIs), H2 receptor antagonists, antacid, and compounds to cause mucosal protection has further advanced the market. Additionally, South Korea's strong healthcare infrastructure, increasing patient awareness, and government regulations to manage development health disorders strongly contributes to market growth.  Despite competition in the market with generic drugs and side effects associated with long term therapy, the Anti-Peptic Ulcer drug market in South Korea is due to achieve constant growth to 2035.

Report Coverage

This research report categorizes the market for the South Korea anti-peptic ulcer drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea anti-peptic ulcer drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea anti-peptic ulcer drugs market.

Driving Factors

The market has been driven by the increasing prevalence of GERD and peptic ulcer disease, increased availability of diagnostic endoscopy, an ageing population with greater comorbidity burden, and the high uptake of proton pump inhibitors as standard of care. Expansion of retail and online pharmacy channels and improved reimbursement mechanisms also allow for unlimited access and volume growth in the market.

Restraining Factors

Market growth is restrained by safety concerns about long-term acid suppression, including PPIs, the growing preference for deprescribing efforts, price erosion due to generic competition, and regulatory controls over OTC status in certain drug classes. Adverse events and stewardship programs that limit unnecessary chronic use of PPIs may constrain long-term volume growth.

Market Segmentation

The South Korea anti-peptic ulcer drugs market share is classified into drug type and ulcer type.

• The proton pump inhibitors segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea anti-peptic ulcer drugs market is segmented by drug type into proton pump inhibitors, H2-receptor antagonists, antacids, antibiotics, and others. Among these, the proton pump inhibitors segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to efficacy and accepted use of PPIs to suppress gastric acid secretion. H2-receptor antagonists play an important role, and antibiotics are necessary in H. pylori eradication therapy.

• The gastric ulcer segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea anti-peptic ulcer drugs market is segmented by ulcer type into gastric ulcer, duodenal ulcer, esophageal ulcer, and others. Among these, the gastric ulcer segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the increasing incidence due to diet and stressors. Also, we have seen increases in duodenal ulcers and esophageal ulcers which is growing concurrently, with esophageal ulcer treatment demand trending upwards in response to complications related to GERD.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea anti-peptic ulcer drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AstraZeneca
• Pfizer Inc.
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eisai Co., Ltd.
• Bayer AG
• Johnson & Johnson
• Sanofi S.A.
• Novartis AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea anti-peptic ulcer drugs market based on the below-mentioned segments:

South Korea Anti-Peptic Ulcer Drugs Market, By Drug Type

• Proton Pump Inhibitors
• H2-Receptor Antagonists
• Antacids
• Antibiotics
• Others

South Korea Anti-Peptic Ulcer Drugs Market, By Ulcer Type

• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer
• Others